MedTrace Logo

Middle Meningeal Artery Embolization for Chronic Subdural Hematoma

NCT04065113 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-07-22

No results posted yet for this study

Summary

Endovascular middle meningeal artery (MMA) embolization is an emerging treatment for chronic subdural hematoma (cSDH). There is preliminary data to suggest that this minimally invasive therapy may be more efficacious and equally as safe compared to conventional, more invasive surgery. This study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma as an adjunct to standard treatments, which include medical management and surgical evacuation.

Conditions

  • Chronic Subdural Hematoma

Interventions

PROCEDURE

Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)

Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma

PROCEDURE

Drainage of Subdural Hematoma

Drainage of subdural hematoma via burrhole or craniotomy

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Joshua W Osbun, MD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-19
Primary Completion
2024-08-01
Completion
2025-06-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065113 on ClinicalTrials.gov